tadalafil has been researched along with acy-1215 in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (acy-1215) | Trials (acy-1215) | Recent Studies (post-2010) (acy-1215) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 117 | 1 | 114 |
| Protein | Taxonomy | tadalafil (IC50) | acy-1215 (IC50) |
|---|---|---|---|
| Histone deacetylase 6 | Danio rerio (zebrafish) | 0.09 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.063 | |
| Histone deacetylase 4 | Homo sapiens (human) | 7 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.0861 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.4 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.1116 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.6349 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.1712 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.084 | |
| Histone deacetylase 5 | Homo sapiens (human) | 5 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0463 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W | 1 |
1 other study(ies) available for tadalafil and acy-1215
| Article | Year |
|---|---|
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neuroglia; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship | 2018 |